Nigerian Breast Cancer Risk-Reduction Study (NBCRS)

August 2, 2023 updated by: Agwai Celia Imaria, University of Ibadan

Effects of Risk Assessment and Counselling on Adherence to Risk Reduction Recommendations Among Female Relatives of Breast Cancer Patients in Southwestern Nigeria

The study will be a randomized controlled trial. The aim of the study is to determine the Breast Cancer (BC) risk and to evaluate the effect of BC risk counseling on lifestyle changes and adherence to risk-reduction practices among first-degree female relatives of BC patients in South-West Nigeria. This study's research questions are:

  • What are the Nigeria Breast Cancer Study (NBCS) and Gail models estimates of the BC risk of first-degree female relatives of BC patients in South-West, Nigeria?
  • What are the effects of BC risk assessment and counseling on adherence to breast screening recommendations among first-degree female relatives of BC patients in South-West, Nigeria?
  • What are the effects of BC risk assessment and counseling on adherence to lifestyle risk reduction recommendations among first-degree female relatives of BC patients in South-West, Nigeria?
  • What is the knowledge, attitudes, and perception of first-degree female relatives of BC patients in South-West Nigeria towards genetic testing and BC etiology?
  • What factors predict breast screening among first-degree female relatives of BC patients in South-West Nigeria?
  • What factors predict the time to first BC screening (post-intervention) among first-degree female relatives of BC patients in South-West Nigeria?

Participants will be randomized into the control arm (standard care) and intervention arms of the study. The intervention arm of the study will have a BC risk assessment followed by individualized BC risk counseling. In addition, the intervention arm will receive BC awareness and MammaCare® BSE training. The control arm will receive only standard care comprising BC awareness and MammaCare® BSE training. Both study arms will receive BC screening recommendations and lifestyle modification recommendations.

We hope that the BC risk counseling will improve BC screening practices and modification of risk behaviors and this hypothesis will be tested.

Study Overview

Study Type

Interventional

Enrollment (Actual)

719

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lagos, Nigeria, 101233
        • Lagos State University Teaching Hospital (LASUTH)
      • Lagos, Nigeria, 102215
        • Lagos University Teaching Hospital (LUTH)
    • Osun
      • Ile-Ife, Osun, Nigeria, 5538
        • Obafemi Awolowo University Teaching Hospital Complex (OAUTHC)
    • Oyo
      • Ibadan, Oyo, Nigeria, 200285
        • University College Hospital (UCH)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. First-degree female relatives of histologically diagnosed BC patients in the study sites
  2. Women aged 20 to 75 years of age
  3. Willingness to be contacted after six months for follow-up

Exclusion Criteria:

  1. Personal history of BC
  2. Previous exposure to breast cancer risk assessment and counselling
  3. Absence of intact breasts

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard care (SC)
Participants received one-on-one breast cancer awareness education; one-on-one monthly Breast Self-Examination (BSE) training; general breast cancer screening recommendations; and general lifestyle modification recommendations
Experimental: SC + Risk assessment and counselling
Participants received Standard care as described in the SC arm above in addition to individualized breast cancer risk assessment, individualized breast cancer risk counseling, and lifestyle risk reduction recommendations
Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
Other Names:
  • Risk assessment
Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
Other Names:
  • Counseling

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of BC risk assessment and counselling on adherence to breast screening recommendations among first-degree female relatives of BC patients in South-West Nigeria
Time Frame: 6 months
Questionnaire will be administered to the participants to determine the effects of the intervention on adherence to breast screening practices
6 months
Effects of BC risk assessment and counselling on adherence to lifestyle risk reduction recommendations among first-degree female relatives of BC patients in South-West, Nigeria
Time Frame: 6 months
Questionnaire will be administered to the participants to determine the effects of the intervention on adherence to lifestyle risk reduction practices
6 months
Predictors of BSE among first-degree female relatives of BC patients in South-West Nigeria
Time Frame: 6 months
Statistical analysis will be carried out to determined the independent variables predicting BSE
6 months
Predictors of time to first BC screening post-intervention among first-degree female relatives of BC patients in South-West Nigeria
Time Frame: Baseline
Statistical analysis will be carried out to determined the independent variables predicting first time to BC screening
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the perception of familial BC risk among first-degree female relatives of BC patients in South-West Nigeria.
Time Frame: Baseline
Semi-structured questionnaires will be used to determine the perception of familial BC risk among participants
Baseline
Determine the knowledge of familiar BC risk among first-degree female relatives of BC patients in South-West Nigeria.
Time Frame: Baseline
Semi-structured questionnaires will be used to determine the knowledge of familiar BC risk among participants
Baseline
Determine the knowledge, attitude, and perception towards genetic testing and BC aetiology among first-degree female relatives of BC patients in South-West Nigeria
Time Frame: Baseline
Semi-structured questionnaires will be used to determine the knowledge, attitude, and perception towards genetic testing and BC aetiology among participants
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: OLADOSUN A OJENGBEDE, FMCOG, FWACS, FICS, M.B.B.S, CENTER FOR POPULATION AND REPRODUCTIVE HEALTH (CPRH), UNIVERSITY COLLEGE HOSPITAL, IBADAN
  • Principal Investigator: OLADELE O.O KALE, B.A, M.B, B.Ch, B.A.O, University of Ibadan
  • Principal Investigator: IKEOLUWAPO O. AJAYI, MBBS; PhD, University of Ibadan
  • Principal Investigator: CELIA IMARIA AGWAI, M.P.H; Ph.D., University of Ibadan
  • Study Director: DEZHENG HUO, PhD, University Of Chicago
  • Study Chair: OLUFUNMILAYO OLOPADE, M.D., F.A.C.P, University Of Chicago

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 13, 2017

Primary Completion (Actual)

October 29, 2021

Study Completion (Actual)

October 29, 2021

Study Registration Dates

First Submitted

March 5, 2023

First Submitted That Met QC Criteria

April 17, 2023

First Posted (Actual)

April 28, 2023

Study Record Updates

Last Update Posted (Actual)

August 3, 2023

Last Update Submitted That Met QC Criteria

August 2, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • NHREC/05/01/2008a (UI/UCH ETHICS COMMITTEE)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Individualized breast cancer risk assessment

3
Subscribe